# Targeting ubiquitin-specific peptidase 22 in solid tumours: from ubiquitination to immunotherapy

## TL;DR

This paper reviews how ubiquitin-specific peptidase 22 (USP22) influences tumor biology and immunity, suggesting it could be a target for cancer immunotherapy.

## Contribution

The paper provides new insights into the role of USP22 in tumor biology and immune regulation, highlighting its potential as a therapeutic target.

## Key findings

- USP22 plays a key role in tumor biological processes.
- USP22 is involved in immune regulation and could improve cancer immunotherapy.
- Clarifying USP22's molecular network may lead to novel treatment strategies.

## Abstract

As a deubiquitinating enzyme, the function of ubiquitin-specific peptidase 22 (USP22) in tumours has attracted increasing attention. However, the regulatory mechanism underlying USP22’s tumour biological processes has not yet been thoroughly elucidated. Moreover, considering the importance of USP22 in immune regulation and clinical treatment, targeting USP22 to prevent tumour biological processes and improve immunotherapy is worthy of attention. Given the significance of USP22 in immune cell function and tumour progression, clarifying the molecular regulatory network of USP22 in different types of tumours is necessary. In this review, we summarise how USP22 regulates tumour biology and analyse the key role of USP22 in immune regulation to provide new insights into novel therapeutic strategies.